Production (Stage)
CASI Pharmaceuticals, Inc.
CASI
$1.33
-$0.51-27.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.04% | 94.30% | -11.82% | -59.48% | -59.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.04% | 94.30% | -11.82% | -59.48% | -59.16% |
| Cost of Revenue | 63.51% | 259.79% | 2.74% | -52.03% | -52.55% |
| Gross Profit | 100.39% | -20.47% | -22.06% | -64.57% | -63.65% |
| SG&A Expenses | 39.44% | 3.01% | 31.97% | -17.21% | -11.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 99.96% | -- | -- | -- |
| Total Operating Expenses | 30.45% | 120.90% | 12.72% | -24.04% | -19.15% |
| Operating Income | -11.00% | -159.27% | -54.06% | -19.49% | -26.77% |
| Income Before Tax | -12.83% | -143.85% | -87.98% | 31.39% | -63.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.83% | -143.89% | -87.98% | 30.84% | -63.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.83% | -137.32% | -81.12% | 31.99% | -58.56% |
| EBIT | -11.00% | -159.27% | -54.06% | -19.49% | -26.77% |
| EBITDA | -16.50% | -207.36% | -54.01% | -16.62% | -24.26% |
| EPS Basic | 2.54% | -65.19% | -58.41% | 32.87% | -58.05% |
| Normalized Basic EPS | 3.25% | -87.11% | -77.81% | 2.93% | -56.07% |
| EPS Diluted | 2.54% | -64.58% | -58.41% | 32.87% | -58.05% |
| Normalized Diluted EPS | 3.25% | -87.11% | -77.81% | 2.93% | -56.07% |
| Average Basic Shares Outstanding | 15.77% | 43.16% | 14.32% | 1.31% | 0.32% |
| Average Diluted Shares Outstanding | 15.77% | 43.16% | 14.32% | 1.31% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |